reports
Cheil Worldwide Inc: 1 director
A director at Cheil Worldwide Inc bought 2,000 shares at 18,750.000KRW and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
Metemtur Otelcilik Ve Turizm Isletmeleri A.S: 1 director
A director at Metemtur Otelcilik Ve Turizm Isletmeleri A.S sold 651,575 shares at 16.483TRY and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors o...
Costamare Inc. Sets the Date for Its First Quarter 2024 Results Releas...
Costamare Inc. Sets the Date for Its First Quarter 2024 Results Release, Conference Call and Webcast Earnings Release: Friday, May 10, 2024, Before Market OpensConference Call and Webcast: Friday, May 10, 2024, at 8:30 a.m. ET MONACO, May 07, 2024 (GLOBE NEWSWIRE) -- Costamare Inc. (NYSE:CMRE), announced today that it will release its results for the first quarter ended March 31, 2024 before the market opens in New York on Friday, May 10, 2024. Conference Call Details: On Friday, May 10, 2024 at 8:30 a.m. ET, Costamare’s management team will hold a conference call to discuss the finan...
GROUPE SEB : DECLARATION MENSUELLE DU NOMBRE D’ACTIONS ET DE DROITS DE...
ECULLY, France--(BUSINESS WIRE)-- Regulatory News: Société déclarante Dénomination sociale SEB S.A (Paris:SK) Adresse du siège social 112 Chemin du Moulin Carron, 69130 Ecully-France Marché réglementé Euronext Paris - Compartiment A ISIN FR0000121709 Nombre d’actions et de droits de vote: 31 Mars 2024 30 avril 2024 Actions composant le capital social (1) 55 337 770 55 337 770 Droits de vote théoriques (2) 81 236 563 81 214 286 Droits de vote exerçables 80 268...
VPG Reports Fiscal 2024 First Quarter Results
VPG Reports Fiscal 2024 First Quarter Results MALVERN, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Vishay Precision Group, Inc. (NYSE: VPG), a leader in precision measurement and sensing technologies, today announced its results for its 2024 first fiscal quarter ended March 30, 2024. First Fiscal Quarter Highlights: Revenues of $80.8 million decreased 9.1% from a year ago.Gross profit margin was 43.4%, as compared to 41.9% reported a year ago.Operating margin was 8.6%, as compared to 11.2% reported a year ago.Adjusted operating margin* was 10.0%, as compared to 11.4% reported a year a...
Metals Acquisition Ltd: 1 director
A director at Metals Acquisition Ltd maiden bought 20,079 shares at 12.450USD and the significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...
NNIT A/S: REVENUE GROWTH OF 12.2% AND 5.2% OPERATING MARGIN. FULL-YEAR...
NNIT A/S: REVENUE GROWTH OF 12.2% AND 5.2% OPERATING MARGIN. FULL-YEAR FINANCIAL OUTLOOK IS MAINTAINED Q1 2024 key highlights The first quarter results were as planned on an overall level. Organic revenue growth of 8.0% driven by Region Denmark and Region Europe partly offset by Region US and Region Asia. The performance of our downscaled Region Asia was impacted by continuing headwind and not as expected. Total revenue growth was 12.2% compared with last year.The group operating profit excluding special items increased from DKK 20m in Q1 2023 to DKK 23.9m in Q1 2024, equal to a group ope...
- Russell Waller
Bouygues Telecom Q1 24: Better SR growth - possibly supported by a c...
Bouygues Telecom has reported a solid set of Q1 numbers: SR growth is better at +4.2% y/y from +3.4% y/y, albeit EBITDAaL growth is a little slower at +7.5% y/y from +11.4% y/y in Q4 23. Bouygues and Orange have now both reported, and so we can begin to think about a possible read-across for SFR and Iliad.
Alchip Showed Advanced Process & Packaging Technology at TSMC Technolo...
Alchip Showed Advanced Process & Packaging Technology at TSMC Technology Symposiums San Jose, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Alchip Technologies, Ltd. the high-performance ASIC leader, highlighted its recent accomplishments and future direction at its TSMC’s 2024 Technology Symposium exhibit in Santa Clara, CA, and Workshop in Austin, TX. Central to its theme were its advanced technology, and chiplet design plans. Alchip will also be present at TSMC NA Technology Workshops in Boston, MA, as well as Technology Symposiums in Europe, Taiwan, China, and Japan. At its booth, Alchip f...
Moody's Ratings affirms DBS Taiwan's A2/P-1 deposit ratings; outlook s...
Moody's Ratings (Moody's) has affirmed DBS Bank (Taiwan) Ltd's (DBS Taiwan) foreign currency and local currency long-term and short-term deposit ratings at A2/P-1. Moody's has also affirmed the bank's Baseline Credit Assessment (BCA) at baa3 and Adjusted BCA at a2, foreign currency and local curre...
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Pr...
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates U.S. launch underway for XOLREMDI™ (mavorixafor) in WHIM syndrome XOLREMDI Phase 3 4WHIM clinical trial data published online in Blood, the journal of the American Society of Hematology Presentation of interim clinical data from the ongoing mavorixafor Phase 2 trial in chronic neutropenia expected at a planned company investor event in June 2024 Conference call to be hosted today at 8:30 a.m. ET BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq...
Radware Only Vendor to Receive a Top Score for AI-Enhanced Vulnerabili...
Radware Only Vendor to Receive a Top Score for AI-Enhanced Vulnerability Detection in New GigaOm Report Ranked as a leader in application and API security MAHWAH, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- ® (NASDAQ: RDWR), a leading provider of cyber security and application delivery solutions, today announced that GigaOm has ranked Radware as a Leader and Fast Mover in GigaOm’s 2024 Radar for Application and (AAS) Report. Radware is the only vendor among the 13 security providers evaluated in the report to earn a top score for AI-enhanced vulnerability detection. In addition, Radware rec...
Atkore Inc. Announces Second Quarter 2024 Results
HARVEY, Ill.--(BUSINESS WIRE)-- Atkore Inc. (the “Company” or “Atkore”) (NYSE: ATKR) announced earnings for its fiscal 2024 second quarter ended March 29, 2024. “Atkore achieved solid results in the second quarter having met our projections for Net Sales and exceeding our projections for Adjusted EBITDA and Adjusted Diluted EPS we presented in February,” said Bill Waltz, Atkore President and Chief Executive Officer. “Organic volume grew 6% for the first half of the year while down 1% for the second quarter. We continue to execute our capital deployment model by investing in our business and ...
Esperion Reports First Quarter 2024 Financial Results
Esperion Reports First Quarter 2024 Financial Results – Q1 Total Revenue Grew 467% Y/Y to $137.7 Million, Reflecting Strong Growth Globally – – Q1 U.S. Net Product Revenue Grew 46% Y/Y to $24.8 Million – – Q1 Retail Prescription Equivalents Grew 43% Y/Y and 6% Q/Q, Increased Momentum from Label Expansions Expected Throughout 2024 – – Received U.S. FDA Approval of Broad New Label Expansions for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet, Becoming the First LDL-C Lowering Non-Statins to Prevent Heart Attacks and Reduce Cardiovascular Risk in Prima...
Fractyl Health to Report First Quarter 2024 Financial Results and Prov...
Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024 BURLINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced it will report financial results for the first quarter 2024 and provide business updates after market close on Monday, May 13, 2024. The Company’s management will host a conference call on the same day beginning at 4:30 p.m. ET. A live webc...
Calfrac Reports First Quarter 2024 Results
Calfrac Reports First Quarter 2024 Results CALGARY, Alberta, May 07, 2024 (GLOBE NEWSWIRE) -- Calfrac Well Services Ltd. (“Calfrac” or “the Company”) (TSX: CFW) announces its financial and operating results for the three months ended March 31, 2024. The following press release should be read in conjunction with the management’s discussion and analysis and interim consolidated financial statements and notes thereto as at March 31, 2024. Readers should also refer to the “Forward-looking statements” legal advisory and the section regarding “Non-GAAP Measures” at the end of this press release...
Sun Country Airlines Reports First Quarter 2024 Results
Sun Country Airlines Reports First Quarter 2024 Results Revenue of $311 million, highest first quarter on record(1)GAAP diluted EPS of $0.64 and operating income of $55 millionAdj. diluted EPS(2) of $0.66 and adjusted operating income(2) of $57 million, MINNEAPOLIS, May 07, 2024 (GLOBE NEWSWIRE) -- Sun Country Airlines Holdings, Inc. (“Sun Country Airlines,” “Sun Country,” the “Company”) () today reported financial results for its first quarter ended March 31, 2024. “Sun Country’s diversified business model produced another strong first quarter with margins that we expect to finish at t...
MediciNova Receives Issue Notification for New Patent Covering Extende...
MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast) LA JOLLA, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received an issue notification from the U.S. Patent and Trademark Office for a new patent which covers extended-release oral formulations of MN-166 (ibudilast). This new patent is expected to expire no earlier than September 2040. Th...
Calibre to Provide an Update on the Valentine Gold Mine and Host Its F...
Calibre to Provide an Update on the Valentine Gold Mine and Host Its First Quarter 2024 Financial Results Conference Call on Wednesday, May 15, 2024 VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Calibre (TSX: CXB; OTCQX: CXBMF) (“Calibre” or the “Company”) will provide an update on its 100% owned, fully funded Valentine Gold Mine located in Newfoundland & Labrador, Canada on Wednesday May 15, 2024. Valentine remains on track to reach production during H1, 2025. In addition, the Company will release its first quarter 2024 financial results on Tuesday, May 14, 2024 after the...
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Confere...
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will attend the 2024 RBC Capital Markets Global Healthcare Conference in New York from May 14-15, 2024. Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat on Wednesday, May 15, from 10:00 to 10:25 AM Eastern Time. A live webcast of the session will be available on the Investor section of Aurinia’s website, which can be found About Aurinia Aurinia Pharmaceuticals is a fully integrated biopharm...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.